The "Chinese Expert Consensus on Ocular Surface Diseases Related to Topical Glaucoma Medications (2022)" outlines the impact of ocular surface diseases (OSDs) from long-term glaucoma medication use on patient compliance and quality of life. Developed by the Glaucoma Group of the Chinese Medical Association, it offers evidence-based guidelines on OSD characteristics, mechanisms, risk factors, diagnosis, treatment, and prevention. Key recommendations include personalized medication choices, the use of preservative-free formulations, and considering laser or surgical options for patients with existing ocular surface issues. The consensus highlights the need for regular ocular surface health assessments to improve treatment outcomes and patient well-being.